Jeff Yass’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $908K | Buy |
+45,100
| New | +$812K | ﹤0.01% | 8195 |
|
|
2026
Q1 | – | Sell |
-10,000
| Closed | -$126K | – | 13104 |
|
|
2025
Q4 | $126K | Buy |
+10,000
| New | +$114K | ﹤0.01% | 11313 |
|
|
2025
Q3 | – | Sell |
-37,400
| Closed | -$303K | – | 12294 |
|
|
2025
Q2 | $303K | Sell |
37,400
-13,000
| -26% | -$98K | ﹤0.01% | 10311 |
|
|
2025
Q1 | $422K | Sell |
50,400
-22,000
| -30% | -$184K | ﹤0.01% | 9282 |
|
|
2024
Q4 | $573K | Buy |
72,400
+25,600
| +55% | +$215K | ﹤0.01% | 8330 |
|
|
2024
Q3 | $389K | Buy |
46,800
+3,600
| +8% | +$28.2K | ﹤0.01% | 9049 |
|
|
2024
Q2 | $274K | Sell |
43,200
-22,300
| -34% | -$142K | ﹤0.01% | 9651 |
|
|
2024
Q1 | $397K | Buy |
+65,500
| New | +$369K | ﹤0.01% | 9054 |
|
|
2023
Q3 | – | Sell |
-33,100
| Closed | -$103K | – | 11950 |
|
|
2023
Q2 | $103K | Buy |
33,100
+18,800
| +131% | +$40K | ﹤0.01% | 10930 |
|
|
2023
Q1 | $19.9K | Sell |
14,300
-7,100
| -33% | -$14.1K | ﹤0.01% | 12054 |
|
|
2022
Q4 | $42.6K | Sell |
21,400
-64,900
| -75% | -$145K | ﹤0.01% | 11476 |
|
|
2022
Q3 | $174K | Sell |
86,300
-18,400
| -18% | -$51.6K | ﹤0.01% | 11037 |
|
|
2022
Q2 | $333K | Sell |
104,700
-147,900
| -59% | -$536K | ﹤0.01% | 9289 |
|
|
2022
Q1 | $1.05M | Buy |
252,600
+75,800
| +43% | +$336K | ﹤0.01% | 6978 |
|
|
2021
Q4 | $847K | Sell |
176,800
-210,700
| -54% | -$1.05M | ﹤0.01% | 7736 |
|
|
2021
Q3 | $2.07M | Buy |
387,500
+121,300
| +46% | +$611K | ﹤0.01% | 5756 |
|
|
2021
Q2 | $1.36M | Buy |
266,200
+20,200
| +8% | +$115K | ﹤0.01% | 6907 |
|
|
2021
Q1 | $1.66M | Buy |
246,000
+52,400
| +27% | +$290K | ﹤0.01% | 6381 |
|
|
2020
Q4 | $885K | Buy |
193,600
+94,400
| +95% | +$418K | ﹤0.01% | 6996 |
|
|
2020
Q3 | $385K | Sell |
99,200
-16,400
| -14% | -$70.1K | ﹤0.01% | 8212 |
|
|
2020
Q2 | $550K | Buy |
115,600
+14,900
| +15% | +$61.4K | ﹤0.01% | 7169 |
|
|
2020
Q1 | $350K | Buy |
100,700
+35,800
| +55% | +$152K | ﹤0.01% | 7680 |
|
|
2019
Q4 | $313K | Sell |
64,900
-99,000
| -60% | -$344K | ﹤0.01% | 7932 |
|
|
2019
Q3 | $475K | Buy |
163,900
+110,500
| +207% | +$386K | ﹤0.01% | 7414 |
|
|
2019
Q2 | $383K | Buy |
+53,400
| New | +$546K | ﹤0.01% | 7821 |
|
|
2018
Q3 | – | Sell |
-19,600
| Closed | -$322K | – | 9139 |
|
|
2018
Q2 | $322K | Buy |
+19,600
| New | +$344K | ﹤0.01% | 7689 |
|
Other funds holding AMRX
Jeff Yass's AMRX Position: Q3 2026 in Review
Jeff Yass increased its Amneal Pharmaceuticals (AMRX) stake by 103% in Q3 2026, buying an estimated $406K and bringing the position to 44,292 shares worth $892K. The position accounts for ﹤0.01% of the portfolio, ranked #8242.
Jeff Yass first reported a position in AMRX in Q2 2018 and has held it in 31 quarters since. The position peaked at $16.7M in Q4 2025. 332 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.
- Jeff Yass held 44,292 shares of Amneal Pharmaceuticals worth $892K as of Q3 2026.
- Jeff Yass bought 22,518 Amneal Pharmaceuticals shares in Q3 2026, an estimated $406K.
- Amneal Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #8242 holding.
- Jeff Yass first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 31 quarters since.
- Jeff Yass's Amneal Pharmaceuticals position peaked at $16.7M in Q4 2025.
- 332 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.
Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.